Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular RiskReport as inadecuate

Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk - Download this document for free, or read online. Document in PDF available to download.

Pain Research and Treatment - Volume 2016 2016, Article ID 8538101, 5 pages -

Research ArticleSchool of Pharmacy, Department of Pharmaceutical Systems and Policy, West Virginia University, Morgantown, WV 26506, USA

Received 15 January 2016; Revised 15 July 2016; Accepted 1 August 2016

Academic Editor: Hartmut Göbel

Copyright © 2016 Monira Alwhaibi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To examine the association between the cardiovascular CV risk factors and triptans use among adults with migraine. Methods. A retrospective cross-sectional study design was used. Data were derived from 2009–2013 Medical Expenditure Panel Survey MEPS. The study sample consisted of adults age > 21 years with migraine headache N = 1,652. Multivariable logistic regression was used to examine the relationship between CV risk factors and triptans use. Results. Overall, 21% adults with migraine headache used triptans. Nearly two-thirds 61% of adults with migraine had at least one CV risk factor. A significantly lower percentage of adults with CV risk 18.1% used triptans compared to those without CV risk factors 25.5%. After controlling for demographic, socioeconomic status, access to care, and health status, adults with no CV risk factors were more likely to use triptans as compared to those with one CV risk factor AOR = 1.83, 95% CI = 1.17–2.87. There were no statistically significant differences in triptans use between those with two or more CV risk factors and those with one CV risk factor. Conclusion. An overwhelming majority of adults with migraine had a contraindication to triptans based on their CV risk factors. The use of triptans among adults with migraine and multiple CV risk factors warrants further investigation.

Author: Monira Alwhaibi, Arijita Deb, and Usha Sambamoorthi



Related documents